Restoring antibiotic effectiveness is essential to modern medicine. By overcoming bacterial resistance mechanisms, existing antibiotics can work again, preserving lifesaving treatments & reducing the need to continually develop new drugs.

Viropin has proprietary technology in the form of multiple internationally granted patents & proprietary formulations.

Controlling hospital infections reduces costs & antibiotic use, protects patients & slows antimicrobial resistance.

There is an opportunity to fast-track regulatory status in key markets.

Global expansion through strategic partnerships enables clinical development, regulatory access & commercial distribution across North America, Europe, Asia, the Middle East & other healthcare markets.

Viropin has secured international commercial partnerships and will achieve scale using a multi-channel revenue model.